Employees: 11-50
Total raised: $71M
Founded date: 2000
Investors 1
| Date | Name | Website |
| - | 3E Biovent... | 3ebiovc.co... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 11.09.2020 | Series B | $56M | - |
| 13.01.2017 | Series A | $15M | - |
Mentions in press and media 9
| Date | Title | Description |
| 07.07.2022 | Africa strikes deal with Pfizer for Covid-19 antiviral — report | Roger Perlmutter is spending his last days at Merck, well, spending. Two weeks after snapping up the antibody-drug conjugate biotech VelosBio for $2.75 billion, Merck announced today that it had purchased OncoImmune and its experimental Cov... |
| 11.09.2020 | HMCapital co-leads $56m Series B in US pharma firm OncoImmune | Premium OncoImmune, Inc., a US-based innovative pharmaceutical firm announced on Thursday that it has garnered $50 million in a Series B round led by HM Capital and an undisclosed blue-chip investor. Continue reading this story with a subsc... |
| 10.09.2020 | OncoImmune Raises $56M Series B Financing | OncoImmune, Inc., a Rockville, Md.-based clinical-stage biopharmaceutical company, completed a $56m Series B equity financing. The round was co-led by HM Capital and a blue-chip investor. Existing investors, 3E Bioventures Capital and Kaita... |
| 09.09.2020 | OncoImmune Raises $56 Million Series B | ROCKVILLE, Md.--(BUSINESS WIRE)--OncoImmune, Inc. announced the completion of a $56 million financing in Series B equity co-led by HM Capital and a blue-chip investor. Existing investors, 3E Bioventures Capital and Kaitai Capital, as well a... |
| 09.09.2020 | OncoImmune, Inc. Raises $56 Million Series B Financing for Novel Cancer and COVID-19 Therapeutics | - |
| 13.01.2017 | OncoImmune Announces $15M in Series A | ROCKVILLE, MD, OncoImmune, Inc. today announced that is has closed on a $15.0 million Series A round of fundraising led by 3E Bioventures. >> Click here for more funding data on OncoImmune >> To export OncoImmune funding dat... |
| 12.01.2017 | OncoImmune Raises $15M Series A | ROCKVILLE, Md.--(BUSINESS WIRE)--OncoImmune, Inc. today announced that is has closed on a $15.0 million Series A round of fundraising led by 3E Bioventures Capital. The new capital will be used primarily to develop a novel clinical stage as... |
| 12.01.2017 | OncoImmune Raises $15M Series A | ROCKVILLE, Md.--(BUSINESS WIRE)--OncoImmune, Inc. today announced that is has closed on a $15.0 million Series A round of fundraising led by 3E Bioventures Capital. The new capital will be used primarily to develop a novel clinical stage as... |
| 12.01.2017 | OncoImmune Closes $15.0M Series A Funding Round | OncoImmune, a Rockville, Maryland clinical-stage biopharmaceutical company, closed $15.0m Series A funding round. The round was led by 3E Bioventures Capital. The company intends to use the funds to develop a novel clinical stage asset targ... |